TO THE EDITOR:
We commend Rickwood and colleagues 1 for presenting aggregated data from headspace centres. However, to judge whether headspace is meeting its key policy objectives, more detailed information is required. No performance benchmarks were proposed for the national program or for the constituent centres. Specifi cally, the variance in key characteristics (age, sex, Aboriginal and Torres Strait Islander populations, rurality, socioeconomic status and current disability) of young people attending the individual centres was not described. As headspace centres were initially placed in areas of need (ie, non-urban, low socioeconomic status, fewer private medical or psychological services, or high Aboriginal and Torres Strait Islander populations), one might expect to see evidence of enhanced access for those with disability or fi nancial hardship. For example, at the University of Sydney-managed headspace sites, 25% of young people were receiving fi nancial assistance and "the same fraction (were) completely disconnected from employment or education" (emphasis added).
2 Internationally, youthtargeted mental health services are being encouraged to focus on such disadvantaged individuals. 3 In Australia, 12% of youth are in this category, and the proportion varies signifi cantly by geographical region (7%-35%). 4 These proportions are not the same as those reported by Rickwood et al 1 (29% in the headspace cohort and 27% in the Australian population), where the measure used appears to be that of not participating fully in employment or education. Given that the economic and social justifi cations for early intervention are focused on enhancing such participation rates, 5 clarifi cation of the metrics being reported by headspace is essential. 2 Grenfell replied on behalf of the National Vascular Disease Prevention Alliance, stating that these agents are of the same pharmacological class 3 and that the guidelines recommend using an agent from a different pharmacological class for second-line therapy. Therefore, he argued that the guidelines recommend "against prescribing" these agents in combination.
Ian B Hickie
3 This is incorrect. ACE inhibitors and ARBs are different classes of drugs.
4 ARBs specifi cally inhibit the angiotensin II type 1 receptor whereas ACE inhibitors block production of angiotensin II. ACE inhibitors also degrade peptides such as bradykinin and substance P, which explains why cough and angioedema are frequently seen with ACE inhibitor therapy, but rarely with ARB therapy. This and other pharmacological differences have clinical implications. For example, ACE inhibitor-induced cough or angioedema does preclude the use of an ARB in the same patient. 4 Similarly, one cannot assume these drug classes produce similar clinical outcomes in the absence of evidence.
Even if these drugs were of the same class, the current form of the guidelines only recommends which combination should be used for second-line therapy, not which combinations should be avoided. 1 This is appropriate. Clinicians should not think ACE inhibitors and ARBs should never be combined. Rather, if the choice exists, a different combination should be chosen. Put another way, hypertension should not be inadequately treated just to avoid using this combination. As a result, psychotropic medication -often antipsychotics -may be prescribed on a hypothesis of effi cacy, rather than a diagnosis of a psychotic disorder. Corresponding improvements in challenging behaviour may then be attributed to medication, rather than sedation.
Defi nitive evidence of the effectiveness of antipsychotics in mitigating challenging behaviour is lacking. A seminal trial published in The Lancet found that risperidone was no more useful than placebo in reducing aggression in people with intellectual disability. 4 In contrast, evidence of serious side effects associated with these medications is clear.
5 People with intellectual disability face a higher burden of disease than other Australians; any decision to risk these side effects for an unproven benefi t must be taken with extreme caution.
Australia lags behind the United Kingdom, where experience with intellectual disability is recognised as an essential component of training for general practitioners and psychiatrists. The Royal Australian and New Zealand College of Psychiatrists recently established a special interest group in intellectual disability; while this is a positive step, limited training in the assessment and management of people with intellectual disability continues to compromise optimal treatment. We need guidelines to reduce prescribing of psychotropics to people with intellectual disability without a diagnosis of mental illness, and research in this area is urgently needed to support the development of evidence-based care. When developing guidelines, the NHMRC always includes a consultation phase and Dixon did not raise his concerns during this phase. When his concerns were subsequently brought to NHMRC's attention -just as the guidelines were in the process of being published -the guideline committee agreed to remove examples of nutritional complications as they were open to misinterpretation.
Niki S Edwards
The revised guidelines were issued in October 2013 and Dixon was informed of the amendment. Hence the version of the guidelines cited in Dixon's article does not contain the text with which he took issue in the Journal.
Further, the guidelines are not intended for bariatric surgeons and their teams, as Dixon suggests. The guidelines are specifi cally targeted at primary care management of overweight and obesity. As such they note that "Individual monitoring and follow-up protocols should be determined by the appropriate specialist team or surgeon, in consultation with the primary care health professionals involved".
The evidence base for the guidelines is documented in the accompanying 656-page systematic review, available on the NHMRC website.
2
The NHMRC develops guidelines against a rigorous set of standards that include governance by an expert multidisciplinary committee, a documented evidence review process, strict confl ict of interest management, Data on lifestyle and family health history (including reproductive history, history of breast or other cancers, and chronic illness) have been collected for more than 20% of members through the online EPI-Q Health and Lifestyle Questionnaire. Of the more than 7300 members who completed the EPI-Q, 20% have a prior history of breast cancer, and 75% have no history of any cancer. Other chronic health conditions covered by the questionnaire include asthma (20% of members), high blood pressure (16%), and osteoarthritis and osteoporosis (12%). Over 60% of participants have never smoked.
To contact Register4 members or access their data, cancer researchers join Register4 as a researcher member, then submit proposals to the Register4 Access Committee for approval. All projects must be fully funded and approved by a human research ethics committee (HREC). The operation of Register4 has HREC approval.
To date, Register4 has been used to recruit participants for 18 cancer research projects, involving nearly 13 000 members. Ample and appropriate participants were recruited within days -dramatically faster than conventional recruitment, which typically takes years.
More information about Register4 can be found at the website (https:// www.register4.org.au) or obtained via email (info@register4.org.au) or by telephone (1300 709 485). alison.butt@nbcf.org.au with this premise. Best informs us that a sports medicine training facility at Falls Creek would "combine the current medical service and teaching arrangements with a new model for year-round sports training in a 'clean' environment".
The Australasian College of Sports Physicians (ACSP) has had a full-time, 4-year advanced training program in sport and exercise medicine since 1992. Sport and exercise medicine is recognised as a medical specialty by the Australian Medical Council (AMC), and the ACSP training program is an AMC-accredited specialist training program. Best's article could easily be interpreted as suggesting that current training in sports medicine lacks ethical content and is confi ned to the concerns of the elite athlete. The vast majority of patients seen by sport and exercise medicine physicians have no involvement in elite sport, and many would not consider themselves "athletes" in any sense of the word. The practice of sport and exercise medicine focuses on removing obstacles to physical activity for individuals of all ages and exercise capacities.
The ACSP training program has a heavy emphasis on ethical practice, evidence-based nutrition, physical activity as a therapeutic intervention, and antidoping education. While it is true that ACSP Fellows are strongly represented in sports medicine leadership positions in Australia and New Zealand, most ACSP Fellows (> 80%) draw no signifi cant revenue stream from high-performance (elite) sport. If there was a perception that sports physicians are only concerned with elite sport and thus lack ethical underpinning, I regret that implication could be drawn from my article. However, as an observer of the health scene, I address as much as I can perceive.
It is refreshing, at a time when there is such uncertainty about the acceptable limits of performance enhancement, that sports physicians should have a strong voice -and for this Hughes must be commended.
